Asahi Kasei Pharma Contracts ProBioGen for the Advancement of their Biologics Pipeline

Asahi Kasei Pharma Contracts ProBioGen for the Advancement of their Biologics Pipeline

Overview

  • Post By :

  • Source: Wire agencies

  • Date: 18 Nov,2020

BERLIN, Germany, November 18, 2020 / B3C newswire / — ProBioGen AG announced the closing of a master service agreement with Asahi Kasei Pharma. As an expert CDMO in high-titer cell line development till large scale GMP manufacturing, ProBioGen will use its proprietary technologies, like the CHO.RiGHT® cell line development platform and DirectedLuck™ transposase technology, to enable Asahi Kasei Pharma to advance their biologics pipeline.
“We are enchanted to work with Asahi Kasei Pharma on one of their key projects and are convinced that we can make a difference by applying our inventive technologies”, said Dr. Gabriele Schneider, Chief Business Officer at ProBioGen.
Osamu Matsuzaki, Senior Executive Officer at Asahi Kasei Pharma added: “After an intense selection process we decided to work with a very experienced and reliable partner as this is critical for the success of our project. We are impressed with ProBioGen’s track record and their deep scientific insights, which led to a tailored development project.”

About Author